Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” second quarter 2025 investor ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark Global Fund” second quarter 2025 investor letter. The fund underperformed its benchmark, the MSCI World Index (net), in the second ...

Becton, Dickinson's divestment enhances focus, reduces leverage, funds buybacks, and unlocks value. Read more about the M&A and why I remain bullish on BDX.

Becton, Dickinson and Company (BDX) develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. Valued at $52.3 billion by market cap, the company ...

BECTON, DICKINSON Hedge Fund Activity We have seen 686 institutional investors add shares of BECTON, DICKINSON stock to their portfolio, and 754 decrease their positions in their most recent quarter.

Becton, Dickinson and Company is an attractive firm that just made a good deal. Click here to find out why BDX stock is a Buy.

Fintel reports that on October 1, 2024, Citigroup upgraded their outlook for Becton, Dickinson and (NYSE:BDX) from Neutral to Buy. As of September 25, 2024, the average one-year price target for ...

Heartland Advisors, an investment management company, released its “Heartland Mid Cap Value Fund” second quarter 2025 ...

On July 11, 2025, Becton, Dickinson and Company (NYSE:BDX) stock closed at $175.97 per share with a market capitalization of $50.434 billion.